WO2006091767A3 - Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors - Google Patents
Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors Download PDFInfo
- Publication number
- WO2006091767A3 WO2006091767A3 PCT/US2006/006513 US2006006513W WO2006091767A3 WO 2006091767 A3 WO2006091767 A3 WO 2006091767A3 US 2006006513 W US2006006513 W US 2006006513W WO 2006091767 A3 WO2006091767 A3 WO 2006091767A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- articles
- compositions
- manufacture
- methods
- contributing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Methods, compositions and articles of manufacture for contributing to the treatment of a solid cancerous tumor are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery of a chemotherapeutic agent to a solid tumor in mammals, including humans.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002598439A CA2598439A1 (en) | 2005-02-22 | 2006-02-22 | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
JP2007557176A JP2008531589A (en) | 2005-02-22 | 2006-02-22 | Methods, compositions and products for contributing to the treatment of solid tumors |
EP06748250A EP1858539A2 (en) | 2005-02-22 | 2006-02-22 | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65565605P | 2005-02-22 | 2005-02-22 | |
US65564305P | 2005-02-22 | 2005-02-22 | |
US65565405P | 2005-02-22 | 2005-02-22 | |
US60/655,654 | 2005-02-22 | ||
US60/655,643 | 2005-02-22 | ||
US60/655,656 | 2005-02-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006091767A2 WO2006091767A2 (en) | 2006-08-31 |
WO2006091767A3 true WO2006091767A3 (en) | 2006-12-28 |
Family
ID=36617185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/006513 WO2006091767A2 (en) | 2005-02-22 | 2006-02-22 | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1858539A2 (en) |
JP (2) | JP2008531589A (en) |
CA (1) | CA2598439A1 (en) |
WO (1) | WO2006091767A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
US8217010B2 (en) | 2002-10-24 | 2012-07-10 | The Board Of Trustees Of The University Of Illinois | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
US20070032422A1 (en) * | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
CN101534852B (en) | 2006-08-31 | 2013-02-13 | 光谱医药公司 | Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
WO2008127996A1 (en) * | 2007-04-13 | 2008-10-23 | Spectrum Pahrmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
US9308235B2 (en) | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040138121A1 (en) * | 2002-10-24 | 2004-07-15 | Anil Gulati | Method and composition for preventing and treating solid tumors |
-
2006
- 2006-02-22 EP EP06748250A patent/EP1858539A2/en not_active Withdrawn
- 2006-02-22 JP JP2007557176A patent/JP2008531589A/en not_active Withdrawn
- 2006-02-22 CA CA002598439A patent/CA2598439A1/en not_active Abandoned
- 2006-02-22 WO PCT/US2006/006513 patent/WO2006091767A2/en active Application Filing
-
2012
- 2012-08-13 JP JP2012179596A patent/JP2012214519A/en active Pending
Non-Patent Citations (10)
Title |
---|
BATTISTINI, B. AND BOTTING, R.: "Endothelins: a quantum leap forward", DRUG NEWS & PERSPECTIVES, vol. 8, no. 6, August 1995 (1995-08-01), pages 365 - 391, XP009029183 * |
BELL, K.M. ET AL.: "Effect of endothelin-1 and sarafotoxin S6c on blood flow in a rat tumor", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 26, no. s3, 1995, pages s222 - s225, XP009029149 * |
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1983, TAKITA H: "Effect of vasodilators in experimental solid tumor chemotherapy", XP002403130, Database accession no. EMB-1983229301 * |
DAVENPORT A P ET AL: "Classification of endothelin receptors and antagonists in clinical development", CLINICAL SCIENCE, BIOCHEMICAL SOCIETY AND THE MEDICAL RESEARCH SOCIETY, LONDON,, GB, vol. 103, no. S48, August 2002 (2002-08-01), pages 1S - 3, XP002277110, ISSN: 0143-5221 * |
JOURNAL OF EXPERIMENTAL AND CLINICAL CANCER RESEARCH 1983 ITALY, vol. 2, no. 1, 1983, pages 47 - 48 * |
RAI AARATI ET AL: "ETB receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumour bearing rats", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 57, no. 7, July 2005 (2005-07-01), pages 869 - 876, XP008066451, ISSN: 0022-3573 * |
RAI, A. AND GULATI, A.: "Evidence for the involvement of ETB receptors in ET-1-induced changes in blood flow to the rat breast tumor", CANCER CHEMOTHER PHARMACOL, vol. 51, 8 November 2002 (2002-11-08), pages 21 - 28, XP001180771 * |
RAJESHKUMAR N V ET AL: "Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats", BREAST CANCER RESEARCH AND TREATMENT, vol. 94, no. 3, December 2005 (2005-12-01), pages 237 - 247, XP002403127, ISSN: 0167-6806 * |
RAJESHKUMAR N V: "ENDOTELIN B RECEPTOR AGONIST, IRL 1260, INCREASES BLOOD PERFUSION AND ENHANCES PACLITAXEL DELIVERY TO TUMOR", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 96, April 2005 (2005-04-01), pages 1349, XP008066444, ISSN: 0197-016X * |
UNIVERSITY OF ILLINOIS AT CHICAGO: "List of Posters Presentations in 2004 AAPS Annual Meeting (Baltimore)", pages 1 - 4, XP002403128, Retrieved from the Internet <URL:http://www2.uic.edu/stud_orgs/prof/aaps/posters.htm> [retrieved on 20061016] * |
Also Published As
Publication number | Publication date |
---|---|
JP2008531589A (en) | 2008-08-14 |
EP1858539A2 (en) | 2007-11-28 |
JP2012214519A (en) | 2012-11-08 |
CA2598439A1 (en) | 2006-08-31 |
WO2006091767A2 (en) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008094708A3 (en) | Activin-actriia antagonists and uses for treating or preventing breast cancer | |
NZ593641A (en) | Extended soluble ph20 polypeptides and uses thereof | |
WO2006119365A3 (en) | Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster | |
WO2006083971A3 (en) | Dr5 antibodies and uses thereof | |
WO2004037235A3 (en) | Method and composition for preventing and treating solid tumors | |
MX2010000465A (en) | Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders. | |
EP2230254A3 (en) | Anti-IGFR1 antibody therapeutic combinations | |
WO2007038868A3 (en) | Novel enediyne compound and uses thereof | |
WO2006034455A3 (en) | Polipeptide compounds for inhibiting angiogenesis and tumor growth | |
WO2006008028A8 (en) | Novel 6-formyltetrahydropteridines method for production and use thereof as medicament against cancer amongst other things | |
WO2008002672A3 (en) | Targets for use in diagnosis, prognosis and therapy of cancer | |
WO2008089397A3 (en) | Adrb2 cancer markers | |
WO2007056049A3 (en) | Molecular profiling of cancer | |
WO2008011519A3 (en) | Amigo-2 inhibitors for treating, diagnosing or detecting cancer | |
WO2007090194A3 (en) | Lymphatic zip codes in tumors and pre-malignant lesions | |
WO2007134210A3 (en) | Methods and compositions for the diagnosis and treatment of cancer | |
WO2006091767A3 (en) | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors | |
EP1868435A4 (en) | Combinations, methods and compositions for treating cancer | |
WO2008061020A3 (en) | Methods of treating, diagnosing or detecting cancer | |
NZ579478A (en) | Epha3 antibodies for the treatment of solid tumors | |
WO2006093813A3 (en) | Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer | |
WO2005085188A3 (en) | Compounds and methods for anti-tumor therapy | |
WO2007120787A3 (en) | Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression | |
WO2007100920A3 (en) | Diagnosis and treatment of prostate cancer | |
WO2008016793A3 (en) | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2006748250 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2598439 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007557176 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |